6.1 Inotropes, Vasopressors & Vasoactive Infusions

6.1 Inotropes, Vasopressors & Vasoactive Infusions

[!NOTE] ANCC Blueprint Focus: Cardiovascular nurses must master the receptor affinities, pharmacodynamics, clinical indications, adverse effects, and bedside titration protocols for continuous vasoactive infusions. This knowledge is heavily tested across Domain II (Planning and Implementation) and Domain III (Evaluation and Modification), particularly regarding hemodynamic management of shock syndromes and acute heart failure.

Vasoactive pharmacotherapy represents the cornerstone of acute hemodynamic resuscitation in critical cardiovascular nursing. Choosing the optimal agent requires an intimate understanding of vascular receptor pharmacology, cardiac cycle mechanics, and cellular signal transduction pathways.

---

Vascular & Myocardial Receptor Pharmacology

Cardiovascular responses to endogenous catecholamines and synthetic vasoactive infusions are governed by specific cell-surface receptors located throughout the myocardium, conduction system, and vascular smooth muscle beds.

                    ┌───> Alpha-1 (Gq) ───> ↑ IP3 / Ca2+ ───> Intense Vasoconstriction (↑ SVR, ↑ MAP)
                    │
Sympathetic /       ├───> Beta-1 (Gs)  ───> ↑ cAMP / PKA ───> ↑ Contractility & Heart Rate (↑ CO, ↑ MVO2)
Vasoactive Receptor ├───> Beta-2 (Gs)  ───> ↑ cAMP / PKA ───> Vasodilation & Bronchodilation (↓ SVR)
Cascades            │
                    ├───> DA-1 (Gs)    ───> ↑ cAMP       ───> Renal / Splanchnic Vasodilation
                    │
                    └───> V1a (Gq)     ───> ↑ IP3 / Ca2+ ───> Non-Adrenergic Vasoconstriction (Acidosis Resistant)

---

Positive Inotropic Agents

Positive inotropes enhance myocardial contractility independent of preload, augmenting stroke volume and cardiac output in low-output heart failure, post-cardiotomy syndrome, and cardiogenic shock.

1. Dobutamine

• Pharmacologic Mechanism: Synthetic catecholamine that acts as a potent $\beta_1$-adrenergic receptor agonist with mild $\beta_2$-agonist and minimal $\alpha_1$-agonist activity.
• Hemodynamic Profile: Augments cardiac index ($CI$) and stroke volume ($SV$) while modestly reducing left ventricular filling pressures (PAOP) and systemic vascular resistance ($SVR$).
• Dosing & Titration: Continuous IV infusion initiated at 2.5 to 5 mcg/kg/min, titrated upward by 2.5 mcg/kg/min increments to a typical clinical range of 2.5 to 20 mcg/kg/min based on cardiac index and clinical perfusion markers.
• Clinical Considerations & Adverse Effects:
  • Significantly increases myocardial oxygen consumption ($MVO_2$); may trigger or worsen myocardial ischemia in acute coronary syndromes.
  • High propensity for inducing tachyarrhythmias (sinus tachycardia, atrial fibrillation, premature ventricular contractions, and non-sustained ventricular tachycardia).
  • Mild $\beta_2$ vasodilation may cause hypotension in hypovolemic patients; adequate intravascular volume must be verified before initiation.
  • Downregulation of $\beta_1$-adrenergic receptors produces pharmacodynamic tolerance (tachyphylaxis) within 48 to 72 hours of continuous administration.

2. Milrinone (Primacor)

• Pharmacologic Mechanism: Selective phosphodiesterase-3 (PDE-3) inhibitor. By inhibiting the breakdown of intracellular cAMP in cardiomyocytes and vascular smooth muscle, milrinone increases cardiac contractility while simultaneously causing systemic and pulmonary arterial and venous dilation—a dual action termed an 'inodilator'.
• Hemodynamic Profile: Increases cardiac index, markedly reduces afterload ($SVR$) and right ventricular afterload (Pulmonary Vascular Resistance, $PVR$), and decreases preload ($PAOP$ and $CVP$) without stimulating adrenergic receptors.
• Dosing & Titration: Maintenance infusion of 0.25 to 0.75 mcg/kg/min. Although the manufacturer labeling includes an optional loading bolus of 50 mcg/kg over 10 minutes, boluses are avoided in clinical heart failure practice due to the severe risk of sudden, refractory systemic hypotension.
• Clinical Pearls & Renal Dosing:
  • Because its mechanism bypasses beta-receptors, milrinone maintains full inotropic efficacy in patients receiving chronic beta-blocker therapy.
  • Highly effective for right ventricular failure secondary to acute or chronic pulmonary hypertension due to its marked pulmonary vasodilatory effects.
  • Elimination & Renal Impairment: Primarily excreted unchanged by the kidneys ($t_{1/2} \approx 2.3\text{ hours}$ in normal renal function, extending to 6 to 10 hours in severe renal dysfunction). Dose reduction is mandatory when creatinine clearance ($CrCl$) falls below $50\text{ mL/min}$.
  • Can trigger severe atrial and ventricular arrhythmias and profound hypotension.

3. Digoxin

• Pharmacologic Mechanism: Cardiac glycoside that reversibly inhibits the myocardial sarcolemmal $Na^+/K^+$ ATPase pump. This increases intracellular sodium, which slows the $Na^+/Ca^{2+}$ exchanger (NCX), driving intracellular calcium accumulation in the sarcoplasmic reticulum and augmenting Phase 2 calcium-induced calcium release (positive inotropy). Concurrently stimulates central vagal (parasympathetic) efferent activity, depressing SA node automaticity and slowing AV nodal conduction (negative chronotropy and dromotropy).
• Therapeutic Serum Concentration: Narrow therapeutic index. Contemporary heart failure guidelines mandate a target serum level of 0.5 to 0.9 ng/mL. Trough levels $>1.0\text{ ng/mL}$ are associated with increased all-cause mortality, particularly in women.
• Electrolyte Sensitivities: Potassium competes with digoxin for the extracellular binding site on the $Na^+/K^+$ ATPase pump.
  • Hypokalemia potentiates digoxin binding, precipitating severe toxicity even at 'normal' serum drug levels.
  • Hypomagnesemia and hypercalcemia similarly amplify digoxin-induced cardiotoxicity.
• Clinical Manifestations of Toxicity:
  • Gastrointestinal: Anorexia, nausea, vomiting, abdominal pain, diarrhea (earliest warning signs).
  • Neurological/Visual: Blurred vision, photophobia, altered color perception (classic yellow-green halos or xanthopsia), confusion, lethargy, delirium.
  • Cardiac Arrhythmias: Frequent premature ventricular contractions (PVCs), ventricular bigeminy, paroxysmal atrial tachycardia with AV block, accelerated junctional rhythm, bidirectional ventricular tachycardia, and high-degree AV blocks.
• Toxicity Management: Discontinue digoxin; correct hypokalemia and hypomagnesemia (maintain potassium between 4.0 and 5.0 mEq/L); administer Digoxin Immune Fab (DigiFab) for life-threatening arrhythmias, hyperkalemia ($K^+ > 5.0\text{ mEq/L}$ in acute ingestion), or acute ingestion $>10\text{ mg}$ in adults.

---

Vasopressor Pharmacology

Vasopressors induce vascular smooth muscle contraction, raising systemic vascular resistance and mean arterial pressure to preserve perfusion to vital organs (brain, heart, kidneys) during profound shock states.

[!IMPORTANT] Epinephrine and Type B Hyperlactatemia: Epinephrine stimulates skeletal muscle $\beta_2$-adrenergic receptors, accelerating glycolysis and cyclic AMP production far beyond mitochondrial pyruvate dehydrogenase clearance capacity. This leads to substantial pyruvate conversion to lactate. This 'aerobic lactate elevation' is a predictable pharmacodynamic phenomenon and must be differentiated from worsening hypoperfusion or refractory shock.

---

Intravenous Vasodilators

Intravenous vasodilators decrease ventricular preload, afterload, or both, lowering myocardial wall stress and optimizing cardiac performance in hypertensive crises and acute pulmonary congestion.

1. Nitroglycerin (Tridil)

• Mechanism: Denitrated in vascular smooth muscle to generate nitric oxide (NO), activating soluble guanylyl cyclase and elevating intracellular cyclic GMP (cGMP) to induce smooth muscle relaxation.
• Hemodynamic Action: At low to moderate infusion rates (5 to 100 mcg/min), acts predominantly as a venodilator, increasing venous capacitance, reducing venous return, and lowering left ventricular end-diastolic volume/pressure ($PAOP$) and right ventricular preload ($CVP$). At higher rates ($>100\text{ mcg/min}$), produces moderate arteriolar dilation, reducing afterload ($SVR$). Selectively dilates epicardial coronary arteries and relieves coronary spasm.
• Clinical Indications: Acute coronary syndromes, acute cardiogenic pulmonary edema, and acute decompensated heart failure with elevated filling pressures.
• Adverse Effects & Tolerance: Throbbing frontal headache, facial flushing, hypotension, and reflex tachycardia. Continuous infusions lasting $>24\text{ to }48\text{ hours}$ lead to nitrate tolerance (tachyphylaxis) due to depletion of intracellular sulfhydryl groups and neurohormonal activation.
• Contraindications: Hypotension ($SBP < 90\text{ mmHg}$), right ventricular infarction (preload-dependent state), and concurrent use of Phosphodiesterase-5 (PDE-5) inhibitors. Concomitant administration of sildenafil or vardenafil within 24 hours, or tadalafil within 48 hours, can cause catastrophic, uncorrectable vasodilation, profound hypotension, and fatal cardiovascular collapse.

2. Sodium Nitroprusside (Nipride)

• Mechanism: Direct non-enzymatic donor of nitric oxide. Does not require metabolic bioactivation, producing immediate, potent, balanced arterial and venous vasodilation.
• Hemodynamic Action: Equally reduces afterload ($SVR$) and preload ($PAOP$), lowering blood pressure while augmenting forward stroke volume in severe vasoconstriction.
• Clinical Indications: Acute hypertensive crises, severe acute aortic regurgitation, acute mitral regurgitation (afterload reduction diminishes regurgitant volume), and acute heart failure with elevated SVR.
• Administration Rules: Extremely photosensitive; must be wrapped in an opaque light-protective sleeve. Solution has an ultra-short half-life (1 to 2 minutes), requiring dedicated infusion lines and continuous intra-arterial blood pressure monitoring.
• Toxicity Surveillance:
  • Each nitroprusside molecule contains five cyanide groups. In RBCs, nitroprusside releases free cyanide, which the liver converts via rhodanese (using thiosulfate donors) to thiocyanate, cleared renally.
  • Cyanide Toxicity: Occurs with rapid, high-dose infusions ($>2\text{ mcg/kg/min}$) or hepatic dysfunction. Cyanide inhibits mitochondrial cytochrome oxidase, halting oxidative phosphorylation. Manifestations include unexplained high anion gap metabolic lactic acidosis, elevated mixed venous oxygen saturation ($SvO_2$, reflecting cellular inability to extract oxygen—histotoxic hypoxia), confusion, and cardiovascular collapse. Treated with sodium thiosulfate or hydroxocobalamin (Cyanokit).
  • Thiocyanate Toxicity: Occurs with prolonged infusions ($>48\text{ hours}$) or renal insufficiency ($CrCl < 30\text{ mL/min}$). Manifestations include tinnitus, hyperreflexia, tremors, disorientation, psychosis, and seizures.

3. Nicardipine (Cardene IV)

• Mechanism: Intravenous dihydropyridine calcium channel blocker that selectively blocks L-type voltage-gated calcium channels in vascular smooth muscle.
• Hemodynamic Action: Potent, highly selective peripheral and cerebral arteriolar vasodilation; significantly reduces $SVR$ and blood pressure with no negative inotropic effect on the myocardium and no impairment of AV nodal conduction.
• Clinical Indications: Hypertensive emergencies, acute ischemic stroke (for BP reduction before/after thrombolysis), acute hemorrhagic stroke, and perioperative cardiac surgical hypertension.
• Titration: Initiated at 5 mg/hr, titrated by 2.5 mg/hr every 5 to 15 minutes to a maximum dose of 15 mg/hr until target blood pressure is reached, then down-titrated to a maintenance rate of 3 mg/hr.

---

Central Line Rules, Extravasation Management & Titration Safety

Vasoactive infusions require rigorous administration standards to prevent tissue injury and hemodynamic instability.

Central Venous vs. Peripheral Infusion Rules

• Mandatory Central Venous Access: Vasopressors (norepinephrine, epinephrine, phenylephrine, vasopressin, high-dose dopamine) are severe vesicants. They must be infused via dedicated central venous catheters (triple-lumen CVC, PICC, or introducer sheath) to prevent peripheral extravasation and ischemic tissue gangrene.
• Emergency Peripheral Administration: In immediate life-threatening resuscitation where central access is pending, vasopressors may be run temporarily through a large-bore peripheral IV (18- or 20-gauge) placed in the antecubital fossa or proximal forearm. Never infuse through small veins of the hand, wrist, or lower extremities. Peripheral vasopressor infusions should be limited to less than 2 to 4 hours while active placement of central venous access is underway. The insertion site must be assessed every 15 minutes for patency, blanching, swelling, and blood return.

Vasopressor Extravasation Protocol (Phentolamine Mesylate)

If peripheral or central extravasation of an adrenergic vasopressor occurs, execute the following emergency nursing protocol:

[ Extravasation Detected ]
       │
       ├──> 1. STOP infusion immediately (DO NOT flush the line)
       ├──> 2. Aspirate residual medication through the catheter hub
       ├──> 3. Remove catheter only after aspiration is completed
       ├──> 4. Notify provider and obtain emergency Phentolamine Mesylate
       ├──> 5. Dilute 5 to 10 mg Phentolamine in 10 to 15 mL normal saline
       ├──> 6. Subcutaneously infiltrate 25-27G needle into blanched area
       │       (Use fine-needle multi-puncture technique throughout ischemic border)
       └──> 7. Monitor for hyperemic flushing and reversal of blanching

• Antidote Mechanism: Phentolamine mesylate is a competitive alpha-adrenergic receptor antagonist that rapidly reverses alpha-1 mediated vasoconstriction, restoring microvascular capillary perfusion. It must be administered within 12 hours of extravasation (ideally immediately).
• Alternative / Adjunctive Therapy: If phentolamine is unavailable, apply topical 2% nitroglycerin paste (1 inch) to the affected area to induce local transdermal vasodilation.

Invasive Arterial Line Monitoring & Titration Standards

• Continuous Intra-Arterial Pressure: All patients requiring continuous titration of vasoactive infusions should have an indwelling arterial line (radial, brachial, or femoral) for beat-to-beat pressure monitoring.
• Zeroing & Transducer Alignment: Ensure the transducer air-fluid interface is precisely leveled to the phlebostatic axis (fourth intercostal space, mid-axillary line, corresponding to the right atrium). Perform a square wave (dynamic response) test at the start of each shift to verify that the system is neither overdamped (underestimating SBP) nor underdamped (overestimating SBP).
• Smart Pumps & Safe Line Swaps: Administer all vasoactive infusions via dedicated smart infusion pumps equipped with Dose Error Reduction Systems (DERS). Dedicated central line lumens must be strictly maintained; never piggyback bolus medications, flushes, or blood products into vasoactive infusion lines. When changing nearly empty syringes or bags, utilize an automated double-pump cross-over technique ('smart pump swap') to avoid hemodynamic collapse from medication interruption or rebound surges from simultaneous dual-infusion boluses.